ICER developed a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies.
Interventions of Interest:
- tisagenlecleucel (KymriahTM , Novartis)
- axicabtagene ciloleucel (YescartaTM, Kite Pharma)
Both agents were approved in 2017. Tisagenlecleucel is approved for treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients. Axicabtagene ciloleucel is approved for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma in adult patients.
Below you will find the final documents from the assessment review process: